Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/26491
Title: | Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting scent implantation: rationale and design of the GLOBAL LEADERS trial | Authors: | VRANCKX, Pascal Valgimigli, Marco Windecker, Stephan Steg, Philippe Gabriel Hamm, Christian Juni, Peter Garcia-Garcia, Hector M. van Es, Gerrit Anne Serruys, Patrick W. |
Issue Date: | 2016 | Source: | EUROINTERVENTION, 12(10), p. 1239-1245 | Abstract: | Aims: The GLOBAL LEADERS trial is a superiority study in patients undergoing percutaneous coronary intervention, with a uniform use of Biolimus A9-eluting stents (BES) and bivalirudin. GLOBAL LEADERS was designed to assess whether a 24-month antithrombotic regimen with ticagrelor and one month of acetylsalicylic acid (ASA), compared to conventional dual antiplatelet therapy (DAPT), improves outcomes. Methods and results: Patients (n >16,000) are randomised (1:1 ratio) to ticagrelor 90 mg twice daily for 24 months plus ASA <= 100 mg for one month versus DAPT with either ticagrelor (acute coronary syndrome) or clopidogrel (stable coronary artery disease) for 12 months plus ASA <= 100 mg for 24 months. The primary outcome is a composite of all-cause mortality or non-fatal, new Q-wave myocardial infarction at 24 months. The key safety endpoint is investigator-reported class 3 or 5 bleeding according to the Bleeding Academic Research Consortium (BARC) definitions. Sensitivity analysis will be carried out to explore potential differences in outcome across geographic regions and according to specific angiographic and clinical risk estimates. Conclusions: The GLOBAL LEADERS trial aims to assess the role of ticagrelor as a single antiplatelet agent after a short course of DAPT for the long-term prevention of cardiac adverse events, across a wide spectrum of patients, following BES implantation. | Keywords: | biolimus A9-eluting stents; dual antiplatelet therapy; monotherapy; percutaneous coronary intervention; ticagrelor | Document URI: | http://hdl.handle.net/1942/26491 | Link to publication/dataset: | https://boris.unibe.ch/75895/1/Vranckx%20EuroIntervention%202016.pdf | ISSN: | 1774-024X | e-ISSN: | 1969-6213 | DOI: | 10.4244/EIJY15M11_07 | ISI #: | 000390981500009 | Rights: | © Europa Digital & Publishing 2016. All rights reserved. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Vranckx EuroIntervention 2016.pdf Restricted Access | Published version | 463.4 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
68
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
85
checked on Jul 26, 2024
Page view(s)
22
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.